This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory tract | 356 |
respiratory viruses | 325 |
acute respiratory | 269 |
nucleic acid | 213 |
respiratory syncytial | 177 |
syncytial virus | 169 |
time pcr | 166 |
respiratory virus | 156 |
human metapneumovirus | 148 |
tract infections | 145 |
lower respiratory | 136 |
respiratory syndrome | 124 |
clin virol | 118 |
virol doi | 118 |
doc id | 118 |
viral load | 118 |
cord uid | 118 |
respiratory infections | 115 |
novel coronavirus | 113 |
severe acute | 111 |
time rt | 109 |
human bocavirus | 109 |
pcr assay | 108 |
influenza viruses | 107 |
avian influenza | 102 |
positive samples | 100 |
influenza virus | 100 |
pcr assays | 96 |
human coronavirus | 94 |
real time | 89 |
copies ml | 87 |
reverse transcription | 83 |
cystic fibrosis | 81 |
ct values | 77 |
chain reaction | 77 |
respiratory specimens | 77 |
polymerase chain | 76 |
young children | 74 |
respiratory samples | 73 |
hong kong | 72 |
human rhinovirus | 72 |
study design | 72 |
viral infections | 72 |
clinical specimens | 71 |
hospitalized patients | 71 |
viral rna | 70 |
tract infection | 65 |
syndrome coronavirus | 65 |
clinical samples | 63 |
coronavirus disease | 61 |
analytical sensitivity | 60 |
respiratory illness | 60 |
previously described | 60 |
public health | 60 |
hospitalized children | 58 |
performed using | 57 |
rna extraction | 57 |
respiratory pathogens | 56 |
united states | 56 |
virus infection | 56 |
respiratory disease | 55 |
cell count | 54 |
multiplex pcr | 54 |
respiratory infection | 54 |
clinical characteristics | 54 |
nucleic acids | 53 |
respiratory viral | 53 |
clinical features | 53 |
viral respiratory | 52 |
tested positive | 51 |
severe respiratory | 49 |
id now | 49 |
upper respiratory | 48 |
parainfluenza virus | 48 |
phylogenetic analysis | 48 |
viral loads | 47 |
pediatric patients | 47 |
nasopharyngeal swabs | 47 |
acquired pneumonia | 46 |
rna viruses | 46 |
gold standard | 46 |
human coronaviruses | 45 |
clinical impact | 45 |
cell culture | 45 |
applied biosystems | 44 |
virus infections | 44 |
respiratory symptoms | 44 |
years old | 44 |
intensive care | 44 |
human respiratory | 43 |
nasal swabs | 43 |
high viral | 42 |
isothermal amplification | 42 |
prevalence rates | 42 |
parainfluenza viruses | 42 |
serum samples | 42 |
infected patients | 41 |
positive results | 40 |
positive patients | 40 |
risk factors | 40 |
mediated isothermal | 39 |
detection rate | 39 |
samples collected | 39 |
acid extraction | 39 |
virus detection | 39 |
rapid tests | 39 |
multiplex real | 38 |
negative samples | 38 |
nadir cd | 38 |
adult patients | 38 |
antigen detection | 38 |
diagnostic tests | 37 |
tract disease | 37 |
time reverse | 37 |
acid amplification | 37 |
negative results | 37 |
viral pathogens | 36 |
disease severity | 36 |
significantly higher | 36 |
human parainfluenza | 36 |
among children | 35 |
rapid detection | 35 |
amino acid | 35 |
viral culture | 35 |
transplant recipients | 35 |
children hospitalized | 35 |
direct rt | 34 |
test results | 34 |
rapid antigen | 34 |
previous studies | 34 |
university hospital | 33 |
present study | 33 |
prospective study | 32 |
testing schemes | 32 |
least one | 32 |
symptom onset | 32 |
clinical performance | 31 |
human influenza | 31 |
human rhinoviruses | 31 |
primer probe | 31 |
nasopharyngeal aspirates | 30 |
coronavirus nl | 30 |
median age | 30 |
reverse transcriptase | 30 |
je virus | 30 |
group testing | 30 |
coronavirus hku | 30 |
nasopharyngeal swab | 30 |
internal control | 29 |
japanese encephalitis | 29 |
infectious diseases | 29 |
infected children | 29 |
highly pathogenic | 29 |
nsp protein | 29 |
cohort study | 28 |
uninfected children | 28 |
molecular assays | 28 |
informed consent | 28 |
infection control | 28 |
commercially available | 28 |
severe disease | 28 |
statistically significant | 27 |
cov infection | 27 |
cytopathic effect | 27 |
patient samples | 27 |
peripheral blood | 27 |
positive control | 27 |
clinical outcomes | 27 |
clinical symptoms | 27 |
health care | 27 |
viral infection | 27 |
study period | 27 |
common respiratory | 27 |
low viral | 27 |
care unit | 27 |
cell counts | 27 |
clinical sensitivity | 26 |
rad kits | 26 |
rsv infection | 26 |
respiratory panel | 26 |
improvement factor | 26 |
transport media | 25 |
rapid test | 25 |
ct value | 25 |
false negative | 25 |
emergency department | 25 |
xpert xpress | 25 |
false positive | 24 |
pcr testing | 24 |
hematologic malignancy | 24 |
rapid diagnosis | 24 |
one patient | 24 |
frequently detected | 24 |
authors declare | 24 |
pcr tests | 24 |
specimens collected | 24 |
diagnostic testing | 24 |
virus type | 24 |
modified cdc | 24 |
spike protein | 24 |
count cells | 24 |
probe sets | 24 |
samples tested | 24 |
tested negative | 24 |
patients infected | 24 |
coronavirus infections | 24 |
symptoms onset | 23 |
xpress sars | 23 |
middle east | 23 |
bronchoalveolar lavage | 23 |
patient management | 23 |
molecular techniques | 23 |
direct assay | 23 |
cerebrospinal fluid | 23 |
pandemic influenza | 23 |
serological tests | 23 |
nervous system | 23 |
pcr reaction | 22 |
laboratory diagnosis | 22 |
clinical manifestations | 22 |
infectious disease | 22 |
rna copies | 22 |
clinical data | 22 |
genetic diversity | 22 |
cobas sars | 22 |
fusion protein | 22 |
clinical presentation | 22 |
molecular diagnostics | 22 |
common cold | 22 |
seasonal influenza | 22 |
positive specimens | 22 |
cdc sars | 21 |
east respiratory | 21 |
stem cell | 21 |
alere tm | 21 |
rpa assays | 21 |
tm influenza | 21 |
pcr positive | 21 |
molecular methods | 21 |
healthy children | 21 |
van den | 21 |
positive cases | 21 |
age group | 21 |
viral shedding | 21 |
world health | 21 |
systematic review | 21 |
ethics committee | 21 |
binax now | 21 |
two different | 21 |
multiplex rt | 20 |
molecular diagnostic | 20 |
tested using | 20 |
high sensitivity | 20 |
clinical evaluation | 20 |
pcr products | 20 |
mean age | 20 |
panther fusion | 20 |
viral nucleic | 20 |
virus isolation | 20 |
acute gastroenteritis | 20 |
high prevalence | 20 |
den hoogen | 20 |
initial nucleic | 20 |
respiratory failure | 20 |
severe cases | 20 |
diagnostic performance | 20 |
amplification assay | 19 |
bacterial infection | 19 |
health organization | 19 |
conventional pcr | 19 |
central nervous | 19 |
hematopoietic stem | 19 |
herpes simplex | 19 |
molecular detection | 19 |
immunocompromised patients | 19 |
transport medium | 19 |
children aged | 19 |
reference method | 19 |
clinical virology | 19 |
lateral flow | 19 |
complete genome | 19 |
medical center | 19 |
children human | 19 |
quality control | 19 |
cell transplant | 19 |
newly discovered | 19 |
acute lower | 19 |
cells transfected | 18 |
samples positive | 18 |
nl infection | 18 |
dual labelled | 18 |
master mix | 18 |
acid test | 18 |
previously published | 18 |
viral transport | 18 |
two viruses | 18 |
coronavirus infection | 18 |
closely related | 18 |
viral etiology | 18 |
viral detection | 18 |
diagnostic assays | 18 |
sars cov | 18 |
new human | 18 |
nested pcr | 18 |
retrospective study | 18 |
rapid diagnostic | 18 |
igg assay | 18 |
pulmonary disease | 18 |
sore throat | 18 |
ct changes | 18 |
generation sequencing | 18 |
lung transplant | 18 |
cytochrome oxidase | 18 |
metapneumovirus infection | 18 |
clinical laboratories | 18 |
total nucleic | 18 |
pool sizes | 17 |
newly identified | 17 |
prevalence rate | 17 |
sars coronavirus | 17 |
low sensitivity | 17 |
control group | 17 |
significant differences | 17 |
positive result | 17 |
cp ml | 17 |
one case | 17 |
children admitted | 17 |
viral dna | 17 |
roche diagnostics | 17 |
influenza infection | 17 |
van der | 17 |
sequence reads | 17 |
ill patients | 17 |
respiratory diseases | 17 |
age groups | 17 |
simultaneous detection | 17 |
abbott sars | 17 |
adult hospitalized | 17 |
sequence data | 17 |
antiviral treatment | 17 |
novel human | 17 |
stool samples | 17 |
viral genome | 17 |
viruses detected | 17 |
previous study | 16 |
study showed | 16 |
extracted rna | 16 |
time assays | 16 |
two assays | 16 |
results obtained | 16 |
blood samples | 16 |
respiratory distress | 16 |
situ rt | 16 |
medical records | 16 |
tract samples | 16 |
recent study | 16 |
relatively low | 16 |
turnaround time | 16 |
mechanical ventilation | 16 |
diagnostic test | 16 |
high throughput | 16 |
like illness | 16 |
molecular epidemiology | 16 |
encephalitis virus | 16 |
lung ct | 16 |
recently published | 16 |
vp vp | 16 |
rhinovirus enterovirus | 16 |
statistical analysis | 16 |
detected viruses | 16 |
acute wheezing | 16 |
ag respi | 16 |
may also | 16 |
antiviral therapy | 16 |
clinical course | 16 |
based assays | 16 |
infection among | 16 |
low positive | 16 |
critically ill | 16 |
one sample | 16 |
coronavirus associated | 16 |
pool size | 15 |
throat swabs | 15 |
two samples | 15 |
serial dilutions | 15 |
tertiary care | 15 |
household contacts | 15 |
sequence analysis | 15 |
rhinovirus infections | 15 |
pcr test | 15 |
mycoplasma pneumoniae | 15 |
human enterovirus | 15 |
assays using | 15 |
rp group | 15 |
virus types | 15 |
written informed | 15 |
detection limit | 15 |
swab samples | 15 |
antibody responses | 15 |
patients hospitalized | 15 |
sample collection | 15 |
children years | 15 |
hrv strains | 15 |
pcr method | 15 |
cycle threshold | 15 |
lysis buffer | 15 |
structural protein | 15 |
der hoek | 15 |
total number | 15 |
exact test | 15 |
pcr methods | 15 |
medical management | 15 |
three assays | 15 |
amino acids | 15 |
samples obtained | 15 |
two patients | 15 |
rights reserved | 15 |
relatively high | 14 |
lower limit | 14 |
acid tests | 14 |
diagnostic laboratories | 14 |
bocavirus infection | 14 |
positive sample | 14 |
time polymerase | 14 |
rv species | 14 |
laboratory developed | 14 |
ml npa | 14 |
stage testing | 14 |
patient care | 14 |
genetic variability | 14 |
virus testing | 14 |
nasopharyngeal specimens | 14 |
complementary studies | 14 |
based elisa | 14 |
cepheid xpert | 14 |
hpiv types | 14 |
current study | 14 |
op na | 14 |
neutralizing antibodies | 14 |
emergency use | 14 |
respiratory pathogen | 14 |
logistic regression | 14 |
two rapid | 14 |
patients tested | 14 |
influenza season | 14 |
vp sequences | 14 |
gene target | 14 |
isothermal nat | 14 |
previously reported | 14 |
single infections | 14 |
monoclonal antibodies | 14 |
respiratory secretions | 14 |
birth weight | 14 |
human transmission | 14 |
swab specimens | 14 |
rna release | 14 |
rapid influenza | 14 |
patients admitted | 14 |
severe pneumonia | 14 |
study demonstrated | 13 |
extracted using | 13 |
time period | 13 |
several studies | 13 |
cov variant | 13 |
chest ct | 13 |
bacterial infections | 13 |
pcr detection | 13 |
health laboratories | 13 |
described previously | 13 |
children younger | 13 |
commercial assays | 13 |
median time | 13 |
large number | 13 |
predictive value | 13 |
viral pathogen | 13 |
immunodeficiency virus | 13 |
different types | 13 |
corresponding author | 13 |
human immunodeficiency | 13 |
toci group | 13 |
even though | 13 |
within days | 13 |
release method | 13 |
genome sequence | 13 |
also tested | 13 |
clinical practice | 13 |
technical assistance | 13 |
clinical diagnosis | 13 |
sensitive detection | 13 |
antigen test | 13 |
molecular beacons | 13 |
multiplex reverse | 13 |
xtag rvp | 13 |
virology laboratory | 13 |
interquartile range | 13 |
wide range | 13 |
simplex virus | 13 |
clinical significance | 13 |
improvement factors | 13 |
avian viruses | 13 |
virus detected | 13 |
control cells | 13 |
abi prism | 13 |
paediatric patients | 13 |
abbott id | 13 |
transcription loop | 13 |
critical cases | 13 |
nasopharyngeal samples | 13 |
nucleotide identity | 13 |
cd cd | 13 |
cdc covid | 13 |
severe lower | 13 |
pathogenic avian | 13 |
foster city | 13 |
oxygen saturation | 13 |
virus panel | 13 |
true positive | 13 |
clinical severity | 13 |
significant difference | 13 |
haemophilus influenzae | 13 |
labelled probes | 13 |
institutional review | 13 |
healthcare workers | 13 |
viral replication | 13 |
variant typing | 12 |
typing assay | 12 |
data collection | 12 |
pcr panel | 12 |
antibody tests | 12 |
care workers | 12 |
antibiotic use | 12 |
hmpv positive | 12 |
review board | 12 |
pcr results | 12 |
igg antibodies | 12 |
time detection | 12 |
otitis media | 12 |
frequent detection | 12 |
transcriptase pcr | 12 |
testing positive | 12 |
cpe positive | 12 |
analytical performance | 12 |
molecular diagnosis | 12 |
detection system | 12 |
np swabs | 12 |
influenza pandemic | 12 |
molecular testing | 12 |
major cause | 12 |
common cause | 12 |
copies per | 12 |
overall sensitivity | 12 |
metagenomic sequencing | 12 |
pcr reactions | 12 |
acute bronchiolitis | 12 |
fully automated | 12 |
study group | 12 |
hospital stay | 12 |
ifa group | 12 |
merkel cell | 12 |
conserved region | 12 |
rapid molecular | 12 |
individual testing | 12 |
ce marked | 12 |
different viruses | 12 |
respiratory illnesses | 12 |
igg igm | 12 |
gb virus | 12 |
highly sensitive | 12 |
streptococcus pneumoniae | 12 |
may explain | 12 |
human parvovirus | 12 |
less sensitive | 12 |
among patients | 12 |
dilution series | 12 |
white blood | 12 |
hrv species | 12 |
test kit | 12 |
pcr reagents | 12 |
disease control | 12 |
percent agreement | 12 |
blood donors | 12 |
coronavirus oc | 12 |
southeast asia | 12 |
transcriptase polymerase | 12 |
based surveillance | 12 |
emergency room | 11 |
rpa assay | 11 |
causative agent | 11 |
clinical disease | 11 |
hrsv rna | 11 |
rhinovirus species | 11 |
discovered human | 11 |
cdc assay | 11 |
mild moderate | 11 |
pulmonary exacerbations | 11 |
cov infections | 11 |
analyzed using | 11 |
viet nam | 11 |
month period | 11 |
cobas assay | 11 |
immune response | 11 |
university medical | 11 |
drug administration | 11 |
amplification tests | 11 |
pcr system | 11 |
positive pcr | 11 |
molecular tests | 11 |
viral diagnosis | 11 |
hospital admission | 11 |
transcription pcr | 11 |
house version | 11 |
detection rates | 11 |
negative panel | 11 |
mcpyv dna | 11 |
leading cause | 11 |
commonly used | 11 |
gestational age | 11 |
use authorization | 11 |
tract specimens | 11 |
reactive protein | 11 |
infections caused | 11 |
negative rt | 11 |
routine clinical | 11 |
fold dilutions | 11 |
realtime pcr | 11 |
symptomatic patients | 11 |
regression analysis | 11 |
icu admission | 11 |
abbott architect | 11 |
hsct recipients | 11 |
one virus | 11 |
significantly lower | 11 |
dromedary camels | 11 |
positive rt | 11 |
san diego | 11 |
hbov infection | 11 |
rhv env | 11 |
among poultry | 11 |
viral agents | 11 |
samples detected | 11 |
detection methods | 11 |
saudi arabia | 11 |
analytical performances | 11 |
multiplex assays | 11 |
step rt | 11 |
widely used | 11 |
wide variety | 11 |
symptomatic travellers | 11 |
copies reaction | 11 |
hbov dna | 11 |
hologic panther | 11 |
rna molecules | 11 |
chronic obstructive | 11 |
positive rate | 11 |
acquired respiratory | 11 |
nl infections | 11 |
filmarray respiratory | 11 |
determine whether | 11 |
group i | 11 |
realstar kit | 11 |
rna virus | 11 |
obstructive pulmonary | 11 |
cell lines | 11 |
small number | 11 |
transcription polymerase | 11 |
patients received | 11 |
using multiplex | 11 |
nucleotide sequences | 11 |
oropharyngeal swabs | 10 |
performance characteristics | 10 |
reference laboratories | 10 |
novel multiplex | 10 |
primary care | 10 |
cell transplantation | 10 |
patient sera | 10 |
matrix gene | 10 |
asian countries | 10 |
roche cobas | 10 |
data analysis | 10 |
testing scheme | 10 |
three different | 10 |
dna viruses | 10 |
mediated amplification | 10 |
idaho technology | 10 |
human embryo | 10 |
patient age | 10 |
proven lrtd | 10 |
ethical approval | 10 |
sample preparation | 10 |
fda eua | 10 |
around time | 10 |
sample size | 10 |
specific grant | 10 |
competing interests | 10 |
per reaction | 10 |
hmpv copies | 10 |
serological assays | 10 |
community acquired | 10 |
novel influenza | 10 |
requiring hospitalization | 10 |
thank dr | 10 |
virus discovery | 10 |
another study | 10 |
human infections | 10 |
human rna | 10 |
multiplex assay | 10 |
using clinical | 10 |
measles infection | 10 |
mini kit | 10 |
among hospitalized | 10 |
high specificity | 10 |
least two | 10 |
csf samples | 10 |
diagnostic methods | 10 |
human polyomaviruses | 10 |
less likely | 10 |
dual infections | 10 |
clinical studies | 10 |
cycling conditions | 10 |
decision making | 10 |
bal samples | 10 |
based assay | 10 |
different respiratory | 10 |
respiratory materials | 10 |
recent studies | 10 |
detect sars | 10 |
phylogenetic trees | 10 |
assay showed | 10 |
hospitalized infants | 10 |
negative result | 10 |
molecular beacon | 10 |
detection test | 10 |
currently available | 10 |
southeast asian | 10 |
standard deviation | 10 |
clinical information | 10 |
emerging respiratory | 10 |
three patients | 10 |
turn around | 10 |
tcid ml | 10 |
clinical respiratory | 10 |
underlying disease | 10 |
serially diluted | 10 |
clinical laboratory | 10 |
hku infection | 10 |
western blot | 10 |
lower cd | 10 |
specimens obtained | 10 |
new zealand | 10 |
one specimen | 10 |
molecular screening | 10 |
aged years | 10 |
study aimed | 10 |
rhinovirus infection | 10 |
hematologic malignancies | 10 |
vp gene | 10 |
genome sequencing | 10 |
multiplex molecular | 10 |
negative control | 10 |
nsp gene | 10 |
respiratory specimen | 10 |
pcr amplification | 10 |
test performance | 10 |
time point | 10 |
year old | 10 |
automated immunoassays | 9 |
large proportion | 9 |
slightly higher | 9 |
airline travellers | 9 |
excellent sensitivity | 9 |
pcr using | 9 |
urgent need | 9 |
rapid identification | 9 |
neg neg | 9 |
acute mi | 9 |
host range | 9 |
lung transplantation | 9 |
respiratory sample | 9 |
developed test | 9 |
using spss | 9 |
throat saliva | 9 |
universal transport | 9 |
retrospective cohort | 9 |
using different | 9 |
using two | 9 |
antigen tests | 9 |
magna pure | 9 |
current guidelines | 9 |
among infants | 9 |
determined using | 9 |
nucleotide duplications | 9 |
respiratory material | 9 |
multiplex nat | 9 |
national institute | 9 |
broadly multiplexed | 9 |
table shows | 9 |
primer set | 9 |
linked immunosorbent | 9 |
phylogenetic analyses | 9 |
antibiotic treatment | 9 |
clinical presentations | 9 |
quantitative real | 9 |
newly designed | 9 |
stage schemes | 9 |
enhancing antibodies | 9 |
participants detected | 9 |
severe critical | 9 |
children less | 9 |
significantly associated | 9 |
gastrointestinal symptoms | 9 |
house assay | 9 |
accession numbers | 9 |
without rna | 9 |
infections among | 9 |
heat inactivation | 9 |
funding agencies | 9 |
negative specimens | 9 |
infections due | 9 |
bal specimens | 9 |
continuous variables | 9 |
specimen types | 9 |
distress syndrome | 9 |
samples testing | 9 |
stage group | 9 |
cp rxn | 9 |
otherwise healthy | 9 |
specimen processing | 9 |
nucleotide sequence | 9 |
aseptic meningitis | 9 |
west nile | 9 |
tonsillar tissues | 9 |
antibiotic prescriptions | 9 |
hepatic involvement | 9 |
human adenovirus | 9 |
sequence alignment | 9 |
authors thank | 9 |
also detected | 9 |
statistical analyses | 9 |
pediatric emergency | 9 |
sputum samples | 9 |
early detection | 9 |
acid identity | 9 |
controlled trial | 9 |
two groups | 9 |
receptor binding | 9 |
older adults | 9 |
previous reports | 9 |
nasopharyngeal aspirate | 9 |
fatality rate | 9 |
median ct | 9 |
bp fragment | 9 |
reference standard | 9 |
igg abs | 9 |
frequently identified | 9 |
observational study | 9 |
diasorin simplexa | 9 |
tract illness | 9 |
cd ratio | 9 |
group ii | 9 |
recent years | 9 |
routine respiratory | 9 |
developing countries | 9 |
strong positive | 9 |
nile virus | 9 |
year study | 9 |
positive test | 9 |
viruses including | 9 |
tobacco exposure | 9 |
pulmonary exacerbation | 9 |
molecular characterization | 9 |
online version | 9 |
low number | 9 |
preventive measures | 9 |
dna polymerase | 9 |
molecular biology | 8 |
data showed | 8 |
samples containing | 8 |
extraction kits | 8 |
capture probes | 8 |
clinical isolates | 8 |
disease associated | 8 |
lower sensitivity | 8 |
different prevalence | 8 |
chest radiography | 8 |
mean log | 8 |
underlying conditions | 8 |
correctly identified | 8 |
protective immunity | 8 |
pcr kit | 8 |
also thank | 8 |
rna polymerase | 8 |
metapneumovirus infections | 8 |
throat swab | 8 |
transcribed rna | 8 |
assay using | 8 |
human disease | 8 |
none declared | 8 |
confirmed cases | 8 |
study shows | 8 |
magna lc | 8 |
also found | 8 |
automated extraction | 8 |
vp region | 8 |
also included | 8 |
taqman rt | 8 |
one child | 8 |
pcr product | 8 |
research ethics | 8 |
risk factor | 8 |
patients years | 8 |
results may | 8 |
human viruses | 8 |
antiviral drugs | 8 |
square test | 8 |
specific detection | 8 |
detect viruses | 8 |
human cases | 8 |
single test | 8 |
external quality | 8 |
antimicrobial treatment | 8 |
lung disease | 8 |
symptoms associated | 8 |
genomic dna | 8 |
four hcovs | 8 |
five samples | 8 |
stranded dna | 8 |
first study | 8 |
routine use | 8 |
agarose gel | 8 |
compared using | 8 |
air travellers | 8 |
virus rna | 8 |
nasal swab | 8 |
cov genomes | 8 |
acute flaccid | 8 |
factors associated | 8 |
clinical use | 8 |
high frequency | 8 |
european countries | 8 |
nasal washings | 8 |
oxygen therapy | 8 |
research use | 8 |
human enteroviruses | 8 |
vitro transcribed | 8 |
diagnostic tool | 8 |
fecal samples | 8 |
emerging viruses | 8 |
demographic characteristics | 8 |
proficiency panel | 8 |
positive predictive | 8 |
severe bronchiolitis | 8 |
positive lrtis | 8 |
population testing | 8 |
clinical implications | 8 |
moderate cases | 8 |
whole genome | 8 |
log copies | 8 |
infectious agent | 8 |
analysis showed | 8 |
genetic lineages | 8 |
clinical specimen | 8 |
tract symptoms | 8 |
cause severe | 8 |
cumulative incidence | 8 |
extraction step | 8 |
inclusion criteria | 8 |
immunocompetent individuals | 8 |
influenza patients | 8 |
lamp reaction | 8 |
circulation patterns | 8 |
euroimmun sars | 8 |
test kits | 8 |
winter months | 8 |
house developed | 8 |
analysis using | 8 |
considered significant | 8 |
epidemiological features | 8 |
acute care | 8 |
control measures | 8 |
specific primers | 8 |
human population | 8 |
positive nucleic | 8 |
rsv infections | 8 |
commercial assay | 8 |
patient testing | 8 |
patients presenting | 8 |
culture supernatants | 8 |
using real | 8 |
rna load | 8 |
hrsv etiology | 8 |
specific antibody | 8 |
sputum specimens | 8 |
serology testing | 8 |
orf ab | 8 |
acid sequences | 8 |
clinical signs | 8 |
embryo lung | 8 |
hbov positive | 8 |
considered positive | 8 |
confidence intervals | 8 |
specific real | 8 |
detecting sars | 8 |
korean children | 8 |
sample processing | 8 |
new york | 8 |
routine diagnostic | 8 |
full length | 8 |
comparative analysis | 8 |
surveillance system | 8 |
multiple respiratory | 8 |
probe set | 8 |
infected individuals | 8 |
human polyomavirus | 8 |
hospitalized adults | 8 |
clinical relevance | 8 |
reaction volume | 8 |
new coronavirus | 8 |
molecular evolutionary | 8 |
extraction methods | 8 |
cardiovascular complications | 8 |
significantly different | 8 |
healthy blood | 8 |
blood cell | 8 |
assay performance | 8 |
fondazione irccs | 8 |
extraction system | 7 |
length genomes | 7 |
sars patients | 7 |
calculated using | 7 |
dual infection | 7 |
sialic acid | 7 |
salt lake | 7 |
hrv serotypes | 7 |
children presenting | 7 |
biofire diagnostics | 7 |
much lower | 7 |
performed according | 7 |
lrt specimens | 7 |
test sensitivity | 7 |
novel avian | 7 |
newly emerging | 7 |
children infected | 7 |
blood mononuclear | 7 |
virus dna | 7 |
pcr diagnostic | 7 |
based pcr | 7 |
respiratory rna | 7 |
clinical care | 7 |
amplification assays | 7 |
rtpcr methods | 7 |
among young | 7 |
diagnostic sensitivity | 7 |
remains unclear | 7 |
sybr green | 7 |
scale population | 7 |
previously healthy | 7 |
host cell | 7 |
syncytial viruses | 7 |
pneumonia requiring | 7 |
cov non | 7 |
recently described | 7 |
multiplex detection | 7 |
three wuv | 7 |
first year | 7 |
genetic reassortment | 7 |
amplification test | 7 |
positivity rates | 7 |
positive children | 7 |
hospitalised children | 7 |
taken together | 7 |
hbov alone | 7 |
virus culture | 7 |
hrsv infection | 7 |
probe sequences | 7 |
extraction kit | 7 |
clinical importance | 7 |
infections human | 7 |
detection assays | 7 |
least days | 7 |
hpiv detections | 7 |
serum specimens | 7 |
sequence variation | 7 |
diagnostic laboratory | 7 |
pediatric cases | 7 |
using pcr | 7 |
quantitative reverse | 7 |
two cohorts | 7 |
csf hsv | 7 |
runny nose | 7 |
considered statistically | 7 |
hrv ev | 7 |
using samples | 7 |
another limitation | 7 |
supplemental table | 7 |
clinically relevant | 7 |
mrp assays | 7 |
cost per | 7 |
laboratory testing | 7 |
flaccid paralysis | 7 |
virus subtypes | 7 |
antibody assays | 7 |
positive sars | 7 |
hsv pcr | 7 |
missing data | 7 |
different assays | 7 |
four human | 7 |
detected positive | 7 |
mortality rate | 7 |
higher prevalence | 7 |
newly described | 7 |
around times | 7 |
polymerase amplification | 7 |
recombinase polymerase | 7 |
adverse clinical | 7 |
high ct | 7 |
overall agreement | 7 |
direct immunofluorescence | 7 |
birth cohort | 7 |
protein gene | 7 |
epithelial cells | 7 |
patient specimens | 7 |
pcr systems | 7 |
higher viral | 7 |
rna detection | 7 |
supplementary table | 7 |
high level | 7 |
respiratory rate | 7 |
lake city | 7 |
molecular assay | 7 |
using primers | 7 |
clinical outcome | 7 |
multiple viral | 7 |
many countries | 7 |
primer pair | 7 |
recently reported | 7 |
empiric antibiotic | 7 |
rt pcr | 7 |
obtained using | 7 |
vitro diagnostic | 7 |
alere i | 7 |
detection tests | 7 |
sensitive method | 7 |
southern china | 7 |
virus isolates | 7 |
extraction reagents | 7 |
oxidase ii | 7 |
mononuclear cells | 7 |
commonly detected | 7 |
architect sars | 7 |
cytokine storm | 7 |
pathogen detection | 7 |
microbiology laboratory | 7 |
virology laboratories | 7 |
nucleocapsid gene | 7 |
presenting symptoms | 7 |
first two | 7 |
prism sequence | 7 |
positive controls | 7 |
multivariate analysis | 7 |
viruses found | 7 |
gram stain | 7 |
working group | 7 |
coding region | 7 |
rapid lateral | 7 |
one month | 7 |
infected pneumonia | 7 |
viral concentrations | 7 |
asymptomatic children | 7 |
cell subsets | 7 |
six patients | 7 |
gene sequences | 7 |
diagnostic virology | 7 |
life technologies | 7 |
structural proteins | 7 |
current pandemic | 7 |
sensitive molecular | 7 |
three multiplex | 7 |
two children | 7 |
infections may | 7 |
automated immunoassay | 7 |
specimen collection | 7 |
sequenced using | 7 |
also showed | 7 |
wheezing children | 7 |
assessed using | 7 |
infection rate | 7 |
profit sectors | 7 |
comparative evaluation | 7 |
associated coronavirus | 7 |
seasonal distribution | 7 |
molecular evolution | 7 |
rtpcr assays | 7 |
confidence interval | 7 |
samples received | 7 |
samples negative | 7 |
retrospective nature | 7 |
negative sample | 7 |
direct comparison | 7 |
multiple infections | 7 |
detect respiratory | 7 |
mail address | 7 |
stool specimens | 7 |
assay kit | 7 |
single center | 7 |
like symptoms | 7 |
copy number | 7 |
lymphocyte subsets | 7 |
immunocompromised hosts | 7 |
patients presented | 7 |
increasing number | 7 |
may represent | 7 |
free area | 7 |
input volume | 7 |
high risk | 7 |
blood cells | 7 |
biofire rp | 7 |
health workers | 7 |
run time | 7 |
acid residues | 7 |
human metapneumoviruses | 7 |
positive agreement | 7 |
pcr analysis | 7 |
amplified using | 7 |
room temperature | 7 |
signal drift | 7 |
virus shedding | 7 |
viruses isolated | 7 |
diagnostic yield | 7 |
viruses causing | 7 |
recombinant protein | 7 |
future studies | 7 |
patient populations | 7 |
tertiary university | 7 |
coronaviruses nl | 6 |
detection using | 6 |
new species | 6 |
genome regions | 6 |
associated pneumonia | 6 |
probably due | 6 |
sequence detection | 6 |
soc group | 6 |
hematopoietic cell | 6 |
one study | 6 |
test result | 6 |
immune evasion | 6 |
organ transplantation | 6 |
results reported | 6 |
infectious episodes | 6 |
total reaction | 6 |
pools containing | 6 |
low cd | 6 |
last years | 6 |
beckman coulter | 6 |
asymptomatic infection | 6 |
ld rt | 6 |
human populations | 6 |
infections including | 6 |
panel assay | 6 |
reaction component | 6 |
zoster virus | 6 |
infectious agents | 6 |
age distribution | 6 |
multiple viruses | 6 |
additional studies | 6 |
collected nasal | 6 |
false positives | 6 |
higher number | 6 |
atypical bacteria | 6 |
laboratories may | 6 |
confirmed human | 6 |
epidemiological studies | 6 |
rad kit | 6 |
diagnostic accuracy | 6 |
quality assessment | 6 |
antibody response | 6 |
immunocompromised children | 6 |
see front | 6 |
developed assays | 6 |
positivity rate | 6 |
genbank accession | 6 |
step real | 6 |
pediatric intensive | 6 |
rna using | 6 |
coronavirus spike | 6 |
sample volume | 6 |
national reference | 6 |
multiplexed pcr | 6 |
symptoms reported | 6 |
highest prevalence | 6 |
whole blood | 6 |
igg positive | 6 |
patients treated | 6 |
ev laboratory | 6 |
specific antibodies | 6 |
assays based | 6 |
iga elisa | 6 |
negative agreement | 6 |
hrv infections | 6 |
per sample | 6 |
respiratory support | 6 |
influenza strains | 6 |
severe diseases | 6 |
nosocomial infection | 6 |
molecular test | 6 |
detection sensitivity | 6 |
rna quantification | 6 |
please note | 6 |
academic medical | 6 |
control groups | 6 |
secondary structure | 6 |
influenza rt | 6 |
asthma exacerbation | 6 |
policlinico san | 6 |
cellular apparatus | 6 |
pcr kits | 6 |
much higher | 6 |
specimen volume | 6 |
clinical associations | 6 |
xtag respiratory | 6 |
assay detected | 6 |
medical care | 6 |
epidemiological profile | 6 |
viral targets | 6 |
amplification testing | 6 |
clinical management | 6 |
reliable detection | 6 |
cell polyomavirus | 6 |
i influenza | 6 |
mild respiratory | 6 |
gene fragments | 6 |
required hospitalization | 6 |
san matteo | 6 |
staphylococcus aureus | 6 |
will allow | 6 |
high genetic | 6 |
igg antibody | 6 |
positive respiratory | 6 |
two years | 6 |
patients aged | 6 |
rpa primers | 6 |
pneumovirus isolated | 6 |
total time | 6 |
host cells | 6 |
igg detection | 6 |
specimens submitted | 6 |
relatively short | 6 |
one hundred | 6 |
wuv real | 6 |
genomic rna | 6 |
better understand | 6 |
broad range | 6 |
nl positive | 6 |
specimens tested | 6 |
months old | 6 |
polyomaviruses ki | 6 |
rna transcripts | 6 |
barr virus | 6 |
antibody detection | 6 |
partially supported | 6 |
categorical variables | 6 |
isoquick rnazol | 6 |
higher rates | 6 |
diseases society | 6 |
two targets | 6 |
distinct hrv | 6 |
negative controls | 6 |
higher levels | 6 |
strains circulating | 6 |
maternal education | 6 |
lamp assay | 6 |
front matter | 6 |
nested rt | 6 |
based strategy | 6 |
disease burden | 6 |
contact tracing | 6 |
individual samples | 6 |
neumodx sars | 6 |
second cohort | 6 |
coronavirus pneumonia | 6 |
irccs policlinico | 6 |
important cause | 6 |
luminex xtag | 6 |
detected using | 6 |
bacterial cultures | 6 |
hrsv load | 6 |
performs best | 6 |
adult cases | 6 |
using rt | 6 |
one hiv | 6 |
enteric virus | 6 |
may cause | 6 |
results suggest | 6 |
rp assay | 6 |
serologic assays | 6 |
bocavirus dna | 6 |
simplexa covid | 6 |
human pneumovirus | 6 |
findings suggest | 6 |
year period | 6 |
nasal washes | 6 |
galapagos islands | 6 |
case fatality | 6 |
adult population | 6 |
pneumonia associated | 6 |
commercial rt | 6 |
assay sensitivity | 6 |
excellent agreement | 6 |
sputum production | 6 |
neutralising antibodies | 6 |
showed high | 6 |
bacterial pneumonia | 6 |
infect humans | 6 |
lung tissue | 6 |
first three | 6 |
jc virus | 6 |
pediatric population | 6 |
acquired rsv | 6 |
blood culture | 6 |
leukocyte count | 6 |
limited number | 6 |
mean ct | 6 |
epidemiological investigations | 6 |
target genes | 6 |
pandemic preparedness | 6 |
person transmission | 6 |
consecutive patients | 6 |
adults hospitalized | 6 |
important role | 6 |
care test | 6 |
severe illness | 6 |
clinical microbiology | 6 |
two consecutive | 6 |
ng biotech | 6 |
also observed | 6 |
children without | 6 |
recent reports | 6 |
retrospectively analyzed | 6 |
viral genomic | 6 |
detected virus | 6 |
common cov | 6 |
mild upper | 6 |
minelute kit | 6 |
respiratory assays | 6 |
probable sars | 6 |
chest radiographs | 6 |
mean number | 6 |
high incidence | 6 |
labelled probe | 6 |
also analyzed | 6 |
causing respiratory | 6 |
illness severity | 6 |
diagnostic tools | 6 |
infections associated | 6 |
kindly provided | 6 |
novel parvovirus | 6 |
strains detected | 6 |
first step | 6 |
purified nucleic | 6 |
north america | 6 |
immunochromatographic assays | 6 |
positive pools | 6 |
genome sequences | 6 |
diagnostic assay | 6 |
winter seasons | 6 |
nasopharyngeal secretions | 6 |
severity score | 6 |
protein expressed | 6 |
anal swabs | 6 |
direct detection | 6 |
cdc eua | 6 |
molecular epidemiological | 6 |
samples may | 6 |
viral encephalitis | 6 |
aquatic birds | 6 |
final concentration | 6 |
within min | 6 |
clinical testing | 6 |
filmarray rp | 6 |
first cohort | 6 |
causative agents | 6 |
lowest lod | 6 |
amplification products | 6 |
influenza diagnosis | 6 |
italian isolates | 6 |
three immunoassays | 6 |
previously identified | 6 |
capsid protein | 6 |
hmpv prevalence | 6 |
samples screened | 6 |
winter season | 6 |
within hours | 6 |
influenza infections | 6 |
ventilated patients | 6 |
immunofluorescence assay | 6 |
differ significantly | 6 |
virus rapid | 6 |
find initiative | 6 |
prospective cohort | 6 |
demographic data | 6 |
odds ratio | 6 |
method using | 6 |
crude specimen | 6 |
data available | 6 |
dna rna | 6 |
pcr negative | 6 |
specific pcr | 6 |
crude material | 6 |
reaction mix | 6 |
parainfluenza type | 6 |
respiratory syndromes | 6 |
pediatric respiratory | 6 |
filmarray detected | 6 |
arti episode | 6 |
studies showed | 6 |
within two | 6 |
personal communication | 6 |
household members | 6 |
causative viruses | 6 |
assay described | 6 |
reported among | 6 |
one assay | 6 |
may lead | 6 |
patients showed | 6 |
infants admitted | 6 |
infected bhk | 6 |
severe covid | 6 |
fibrosis patients | 6 |
per test | 6 |
culture results | 6 |
three influenza | 6 |
large numbers | 6 |
pcr primers | 6 |
control study | 6 |
previously positive | 6 |
plus cough | 6 |
elution volume | 6 |
reverse primer | 6 |
laboratory personnel | 6 |
several viruses | 6 |
randomly selected | 6 |
two systems | 6 |
low level | 6 |
standard curve | 6 |
published data | 6 |
pharyngeal swabs | 6 |
statistical significance | 6 |
virus strains | 6 |
extraction using | 6 |
pathogens identified | 6 |
free water | 6 |
antibodies directed | 6 |
cov variants | 5 |
neutrophil count | 5 |
early visibility | 5 |
healthy adults | 5 |
may provide | 5 |
novel viruses | 5 |
target sequence | 5 |
binding domain | 5 |
clinical illness | 5 |
electron microscope | 5 |
acid recovery | 5 |
neg severe | 5 |
virus strain | 5 |
five years | 5 |
microtiter plate | 5 |
extraction method | 5 |
testing methods | 5 |
children tested | 5 |
lc assay | 5 |
additional copyediting | 5 |
gene fragment | 5 |
bacterial co | 5 |
length mers | 5 |
higher frequency | 5 |
ethics committees | 5 |
also used | 5 |
spss inc | 5 |
give early | 5 |
antibiotic prescribing | 5 |
primer express | 5 |
laboratory features | 5 |
plasma samples | 5 |
also positive | 5 |
patients without | 5 |
also associated | 5 |
high levels | 5 |
except rhv | 5 |
novel real | 5 |
case series | 5 |
different molecular | 5 |
high analytical | 5 |
version will | 5 |
influenza cases | 5 |
nosocomial acquisition | 5 |
glycosylation sites | 5 |
research team | 5 |
reference sequences | 5 |
pcr targeting | 5 |
based studies | 5 |
cost effective | 5 |
low prevalence | 5 |
small numbers | 5 |
johns hopkins | 5 |
radiological findings | 5 |
positive clinical | 5 |
using capture | 5 |
transfected cells | 5 |
statistical package | 5 |
se asia | 5 |
encephalitis management | 5 |
quantitative pcr | 5 |
primers used | 5 |
double positive | 5 |
many laboratories | 5 |
severe morbidity | 5 |
three methods | 5 |
serological testing | 5 |
viral bronchiolitis | 5 |
current arti | 5 |
clinical research | 5 |
table table | 5 |
dna detection | 5 |
panel test | 5 |
high rate | 5 |
commercial multiplex | 5 |
high mortality | 5 |
based testing | 5 |
prototype strains | 5 |
assays may | 5 |
pdf file | 5 |
viral genomes | 5 |
stool sample | 5 |
min followed | 5 |
routine testing | 5 |
three sars | 5 |
viruses using | 5 |
patients included | 5 |
different targets | 5 |
retrospective analysis | 5 |
severe infection | 5 |
amplification reaction | 5 |
another respiratory | 5 |
conserved regions | 5 |
first report | 5 |
elisa kit | 5 |
mm nacl | 5 |
oxygen supplementation | 5 |
tracheal aspirates | 5 |
two standard | 5 |
clinical progression | 5 |
two novel | 5 |
ki polyomavirus | 5 |
observational cohort | 5 |
maximum likelihood | 5 |
resistance mutations | 5 |
viral antigens | 5 |
undiagnosed cases | 5 |
rna rt | 5 |
increasing prevalence | 5 |
specimen type | 5 |
results indicated | 5 |
age range | 5 |
expected virus | 5 |
reaction assay | 5 |
clinical diagnostic | 5 |
distinct human | 5 |
quantitative rt | 5 |
situ reverse | 5 |
traditional methods | 5 |
paediatric hospital | 5 |
enterovirus infections | 5 |
virus sequences | 5 |
fluorescent antibody | 5 |
early diagnosis | 5 |
antiretroviral therapy | 5 |
central hospital | 5 |
production process | 5 |
qiaamp viral | 5 |
emergency unit | 5 |
high number | 5 |
extracted viral | 5 |
legal disclaimers | 5 |
higher analytical | 5 |
rs virus | 5 |
pathogen identification | 5 |
simplex encephalitis | 5 |
sense rna | 5 |
found positive | 5 |
automated rna | 5 |
related conditions | 5 |
now assay | 5 |
cover page | 5 |
viral diseases | 5 |
conventional culture | 5 |
protein interacting | 5 |
results indicate | 5 |
specimens previously | 5 |
using conventional | 5 |
positive patient | 5 |
steric shielding | 5 |
sample types | 5 |
pathogens causing | 5 |
ausdiagnostics ruo | 5 |
six month | 5 |
hsv encephalitis | 5 |
positive percent | 5 |
hiv infection | 5 |
validation studies | 5 |
biocredit covid | 5 |
diagnostic panel | 5 |
identified viruses | 5 |
lamp test | 5 |
may indicate | 5 |
undergo additional | 5 |
undergone enhancements | 5 |
influenza pandemics | 5 |
virus nucleic | 5 |
novel coronaviruses | 5 |
younger age | 5 |
allowed us | 5 |
numbered years | 5 |
surveillance study | 5 |
prolonged shedding | 5 |
cdna synthesis | 5 |
sanger sequencing | 5 |
weak positive | 5 |
hospitalized pediatric | 5 |
recently identified | 5 |
days post | 5 |
conventional rt | 5 |
indirect immunofluorescence | 5 |
binding pocket | 5 |
virus identification | 5 |
samples taken | 5 |
near future | 5 |
epidemic peak | 5 |
respiratory exacerbations | 5 |
data indicated | 5 |
novo assembly | 5 |
isolation kit | 5 |
median duration | 5 |
posterior oropharyngeal | 5 |
children attending | 5 |
conventional viral | 5 |
negative predictive | 5 |
two sars | 5 |
hmpv infection | 5 |
hcov infections | 5 |
antibody screening | 5 |
extraction control | 5 |
acute influenza | 5 |
oral ribavirin | 5 |
uw virology | 5 |
information system | 5 |
genomic materials | 5 |
negative cases | 5 |
took place | 5 |
rvp rp | 5 |
mouth disease | 5 |
six samples | 5 |
lavage fluid | 5 |
malignancy patients | 5 |
samples analyzed | 5 |
rna isolation | 5 |
clinical value | 5 |
related coronavirus | 5 |
acute bronchitis | 5 |
neutralisation assay | 5 |
immunocompetent adults | 5 |
immunocompromised individuals | 5 |
first days | 5 |
causative role | 5 |
pcr efficiency | 5 |
acid sequence | 5 |
bacterial pathogens | 5 |
flow cytometry | 5 |
oseltamivir administration | 5 |
hemagglutination inhibition | 5 |
nsp fusion | 5 |
yeast two | 5 |
assays targeting | 5 |
coding sequence | 5 |
detected hbov | 5 |
different clinical | 5 |
human virome | 5 |
resplex ii | 5 |
two multiplex | 5 |
became available | 5 |
human specimens | 5 |
three kits | 5 |
hrv single | 5 |
identified hrv | 5 |
thermo fisher | 5 |
paediatric population | 5 |
automated assays | 5 |
respiratory seasons | 5 |
rhinovirus prototype | 5 |
rna molecular | 5 |
qiaamp minelute | 5 |
low copy | 5 |
oseltamivir treatment | 5 |
st century | 5 |
empiric antibiotics | 5 |
bronchiolitis cases | 5 |
diagnostic value | 5 |
commercial immunoassays | 5 |
one year | 5 |
graphpad prism | 5 |
poor sensitivity | 5 |
cleavage site | 5 |
complete nucleotide | 5 |
tube scanner | 5 |
symptomatic children | 5 |
acro biotech | 5 |
dn ds | 5 |
pediatric age | 5 |
oropharyngeal saliva | 5 |
healthy individuals | 5 |
gene primers | 5 |
gene targets | 5 |
reference genome | 5 |
wuv conventional | 5 |
pregnant women | 5 |
spanish flu | 5 |
nucleotide duplication | 5 |
corona virus | 5 |
epidemiologically associated | 5 |
journal pertain | 5 |
new virus | 5 |
assay targeting | 5 |
chlamydia pneumoniae | 5 |
frontline testing | 5 |
one target | 5 |
patients attended | 5 |
single virus | 5 |
reductase system | 5 |
using previously | 5 |
higher ct | 5 |
consecutive years | 5 |
circular dna | 5 |
cardiac disease | 5 |
arti patients | 5 |
three cases | 5 |
rheumatoid factor | 5 |
solid organ | 5 |
human infection | 5 |
even higher | 5 |
virus diagnostic | 5 |
coronaviruses oc | 5 |
mico biomed | 5 |
hospital setting | 5 |
joining method | 5 |
older children | 5 |
cdc fda | 5 |
viruses comparison | 5 |
routinely used | 5 |
geq ml | 5 |
buffered saline | 5 |
reference test | 5 |
amplification inhibitors | 5 |
optical density | 5 |
hospitalizations among | 5 |
frequently reported | 5 |
mm tris | 5 |
time taqman | 5 |
nat alere | 5 |
care testing | 5 |
might assist | 5 |
diagnostics inc | 5 |
viral co | 5 |
potential cross | 5 |
samples per | 5 |
resulted positive | 5 |
equivocal results | 5 |
take place | 5 |
tests performed | 5 |
relative performance | 5 |
viral panel | 5 |
bacterial culture | 5 |
severe symptoms | 5 |
new assay | 5 |
study suggests | 5 |
among older | 5 |
sectional study | 5 |
family members | 5 |
routine diagnostics | 5 |
ha gene | 5 |
eight samples | 5 |
fisher scientific | 5 |
specific respiratory | 5 |
total rna | 5 |
suspected covid | 5 |
genetics analysis | 5 |
etiologic role | 5 |
influenza surveillance | 5 |
immunosorbent assays | 5 |
abbott igg | 5 |
virological assessment | 5 |
influenza pcr | 5 |
house nat | 5 |
developed real | 5 |
laboratory findings | 5 |
genes encoding | 5 |
medically attended | 5 |
tract diseases | 5 |
days since | 5 |
enterovirus surveillance | 5 |
conventional methods | 5 |
highly conserved | 5 |
asymptomatic controls | 5 |
routine laboratory | 5 |
virus species | 5 |
log cp | 5 |
study population | 5 |
global pandemic | 5 |
previously tested | 5 |
patient population | 5 |
influenza diagnostic | 5 |
regression model | 5 |
specimen extracts | 5 |
younger children | 5 |
pediatric specimens | 5 |
two respiratory | 5 |
united kingdom | 5 |
case definitions | 5 |
vast majority | 5 |
laboratory tests | 5 |
recovery rates | 5 |
different primer | 5 |
igm rapid | 5 |
infectious virus | 5 |
general hospital | 5 |
urgently needed | 5 |
virus isolated | 5 |
cov emc | 5 |
reported previously | 5 |
specific cellular | 5 |
atypical bacterial | 5 |
observed using | 5 |
enterovirus infection | 5 |
final form | 5 |
common symptoms | 5 |
different rv | 5 |
samples ran | 5 |
standard rt | 5 |
goat anti | 5 |
south africa | 5 |
human igg | 5 |
strains identified | 5 |
organ failure | 5 |
ev positive | 5 |
studies reported | 5 |
probe rt | 5 |
health laboratory | 5 |
will undergo | 5 |
control practices | 5 |
igm lfia | 5 |
clinical pneumonia | 5 |
utr regions | 5 |
initial diagnosis | 5 |
errors may | 5 |
fold serial | 5 |
comprehensive detection | 5 |
definitive version | 5 |
new viruses | 5 |
clinical setting | 5 |
paediatric infectious | 5 |
realtime rt | 5 |
specific serology | 5 |
evaluated using | 5 |
useful tool | 5 |
evolutionary genetics | 5 |
novel virus | 5 |
including human | 5 |
neurological symptoms | 5 |
parvovirus epidemiologically | 5 |
center study | 5 |
published results | 5 |
qce positives | 5 |
significant changes | 5 |
cross reactivity | 5 |
significant impact | 5 |
rapid methods | 5 |
virus may | 5 |
hrv detection | 5 |
high quality | 4 |
patient sample | 4 |
data obtained | 4 |
conjugate vaccine | 4 |
transplant patients | 4 |
antibiotic prescription | 4 |
study found | 4 |
infected mice | 4 |
allogeneic hsct | 4 |
aptima sars | 4 |
symptom screening | 4 |
mitochondrial membrane | 4 |
cov genome | 4 |
gene rt | 4 |
base pair | 4 |
run within | 4 |
pooled primer | 4 |
early summer | 4 |
new onset | 4 |
nt database | 4 |
rsv positive | 4 |
without respiratory | 4 |
main target | 4 |
infection date | 4 |
labeled goat | 4 |
nasopharyngeal oropharyngeal | 4 |
antibody concentration | 4 |
one strain | 4 |
probes targeting | 4 |
ad hoc | 4 |
bd max | 4 |
countries worldwide | 4 |
detect hcov | 4 |
mean duration | 4 |
intravenous antibiotics | 4 |
unknown etiologies | 4 |
qce positive | 4 |
bocavirus infections | 4 |
colorimetric microtiter | 4 |
late fall | 4 |
autoimmune encephalitis | 4 |
technology filmarray | 4 |
cause mortality | 4 |
viral wheeze | 4 |
severe neg | 4 |
pulmonary infiltrates | 4 |
time quantitative | 4 |
sample pools | 4 |
patients suspected | 4 |
additional primers | 4 |
blood units | 4 |
differential diagnosis | 4 |
care worker | 4 |
respiratory picornaviruses | 4 |
cytokine therapy | 4 |
lower airway | 4 |
th century | 4 |
rhinovirus genotype | 4 |
virus screening | 4 |
important etiologic | 4 |
sequences obtained | 4 |
less expensive | 4 |
genetic changes | 4 |
viruses date | 4 |
good specificity | 4 |
classical rna | 4 |
allogeneic hematopoietic | 4 |
considered false | 4 |
better understanding | 4 |
immunofluorescence assays | 4 |
risk adults | 4 |
np samples | 4 |
samples will | 4 |
surface glycoproteins | 4 |
consensus sequences | 4 |
positive viral | 4 |
human pathogens | 4 |
negative patients | 4 |
sequence databases | 4 |
studies comparing | 4 |
also reported | 4 |
rv typing | 4 |
assays evaluated | 4 |
several factors | 4 |
cohen kappa | 4 |
bordetella pertussis | 4 |
patients diagnosed | 4 |
acute disease | 4 |
single sample | 4 |
th june | 4 |
children associated | 4 |
hmpv detection | 4 |
accurate diagnosis | 4 |
pediatric inpatients | 4 |
influenza viral | 4 |
hospitalized due | 4 |
alveolar lavage | 4 |
genetic analysis | 4 |
deep throat | 4 |
per specimen | 4 |
care centre | 4 |
study evaluating | 4 |
writing review | 4 |
patients participating | 4 |
often associated | 4 |
medical record | 4 |
reference strains | 4 |
reagents used | 4 |
ingenius platform | 4 |
patients also | 4 |
fisher exact | 4 |
variants carrying | 4 |
tertiary hospital | 4 |
improved detection | 4 |
bigdye terminator | 4 |
comparative performance | 4 |
infections occur | 4 |
recently discovered | 4 |
results showed | 4 |
pediatric community | 4 |
lopinavir ritonavir | 4 |
mrp assay | 4 |
hmpv negative | 4 |
hmpv cases | 4 |
ethical committee | 4 |
developed respiratory | 4 |
constructed using | 4 |
rsv rt | 4 |
coinfection rates | 4 |
transcription recombinase | 4 |
among immunocompetent | 4 |
international committee | 4 |
emergency departments | 4 |
healthy control | 4 |
acute infection | 4 |
throughput testing | 4 |
performed well | 4 |
may prove | 4 |
reporter dye | 4 |
based detection | 4 |
atcc strains | 4 |
texas medical | 4 |
additional samples | 4 |
aged less | 4 |
amplification methods | 4 |
neuraminidase inhibitor | 4 |
currently circulating | 4 |
ran within | 4 |
van elden | 4 |
higher sensitivity | 4 |
using respiratory | 4 |
viruses among | 4 |
including nasal | 4 |
well known | 4 |
help improve | 4 |
also important | 4 |
exclusion criteria | 4 |
relatively small | 4 |
virus transport | 4 |
rapid diagnostics | 4 |
disease progression | 4 |
institutional ethics | 4 |
data curation | 4 |
hologic aptima | 4 |
virus taxonomy | 4 |
median viral | 4 |
duplications might | 4 |
closed system | 4 |
likely due | 4 |
findings indicate | 4 |
origin influenza | 4 |
clinical spectrum | 4 |
possible cross | 4 |
strain usa | 4 |
acid detection | 4 |
pcr amplicons | 4 |
oxidase complex | 4 |
flow nasal | 4 |
children prevalence | 4 |
ventilated toci | 4 |
sample input | 4 |
highest sensitivity | 4 |
leukemic children | 4 |
primary infection | 4 |
childhood pneumonia | 4 |
features including | 4 |
software version | 4 |
physical examination | 4 |
negative test | 4 |
per pool | 4 |
common co | 4 |
ventilatory support | 4 |
recently available | 4 |
potential role | 4 |
healthy controls | 4 |
new viral | 4 |
exo rna | 4 |
pcr protocols | 4 |
cytokine treatments | 4 |
less frequently | 4 |
evolutionary advantage | 4 |
cardiopulmonary complications | 4 |
standard method | 4 |
kidney transplantation | 4 |
major causes | 4 |
three times | 4 |
samples using | 4 |
worse outcomes | 4 |
good agreement | 4 |
authors also | 4 |
consecutive samples | 4 |
characteristic lung | 4 |
following viruses | 4 |
seroprevalence studies | 4 |
disease presentation | 4 |
required intensive | 4 |
heart failure | 4 |
envelope protein | 4 |
asymptomatic individuals | 4 |
nmda antibodies | 4 |
elisa kits | 4 |
severe enough | 4 |
respiratory epithelial | 4 |
oligonucleotide primers | 4 |
using seven | 4 |
hmpv rt | 4 |
physician decision | 4 |
test samples | 4 |
required admission | 4 |
clinical findings | 4 |
medical research | 4 |
high virulence | 4 |
first strand | 4 |
general population | 4 |
using molecular | 4 |
fever virus | 4 |
rapidly spread | 4 |
lymphocyte counts | 4 |
rvp assay | 4 |
infectious complications | 4 |
multicenter study | 4 |
commonly co | 4 |
possible cause | 4 |
np swab | 4 |
median number | 4 |
routine patient | 4 |
clinical trial | 4 |
virus among | 4 |
bnr positive | 4 |
spss version | 4 |
sequencing kit | 4 |
pcr inhibitors | 4 |
occurred mainly | 4 |
tobias allander | 4 |
routine viral | 4 |
nat assay | 4 |
influenza type | 4 |
assay used | 4 |
david title | 4 |
reduce hands | 4 |
case detection | 4 |
studies evaluating | 4 |
four patients | 4 |
minor group | 4 |
available assays | 4 |
shorter tat | 4 |
molecular weight | 4 |
frozen pcr | 4 |
sh sample | 4 |
hmpv fusion | 4 |
fold higher | 4 |
data suggest | 4 |
evaluate assay | 4 |
clinical performances | 4 |
abbott molecular | 4 |
virological features | 4 |
screening campaigns | 4 |
mers coronavirus | 4 |
european commission | 4 |
pediatric populations | 4 |
virus surveillance | 4 |
identified using | 4 |
care settings | 4 |
rapid flu | 4 |
virus disease | 4 |
wu polyomaviruses | 4 |
specimens included | 4 |
care hospital | 4 |
type infections | 4 |
symptom diaries | 4 |
nasal aspirates | 4 |
qualitative variables | 4 |
multiplexed assay | 4 |
term storage | 4 |
suspected cases | 4 |
associated disorders | 4 |
high demand | 4 |
targets detected | 4 |
pooled samples | 4 |
ns gene | 4 |
associated hospitalizations | 4 |
previously undescribed | 4 |
fold difference | 4 |
disease caused | 4 |
eua methods | 4 |
clinical utility | 4 |
patients requiring | 4 |
rna isolated | 4 |
open access | 4 |
routinely screened | 4 |
np specimens | 4 |
highly specific | 4 |
two methods | 4 |
quantitative detection | 4 |
clinical specificity | 4 |
bootstrap analysis | 4 |
may contribute | 4 |
viral na | 4 |
cells mm | 4 |
pcr result | 4 |
common viruses | 4 |
respiratory coronavirus | 4 |
time frame | 4 |
capsid gene | 4 |
clinical syndromes | 4 |
time multiplex | 4 |
dna recovery | 4 |
age months | 4 |
seriously ill | 4 |
infection diagnosis | 4 |
mild disease | 4 |
added value | 4 |
rapid multiplex | 4 |
infected cells | 4 |
data show | 4 |
reverse genetics | 4 |
months post | 4 |
virus responsible | 4 |
confirmed pneumonia | 4 |
now sars | 4 |
rapid risk | 4 |
mm mgcl | 4 |
early life | 4 |
viruses except | 4 |
first case | 4 |
collection methods | 4 |
nasopharyngeal washes | 4 |
viruses human | 4 |
genetic characterisation | 4 |
mild symptoms | 4 |
pcr cycling | 4 |
suitable alternative | 4 |
routine screening | 4 |
antimicrobial resistance | 4 |
clinical criteria | 4 |
virus bronchiolitis | 4 |
sample storage | 4 |
higher rate | 4 |
transcription factor | 4 |
data sets | 4 |
increased use | 4 |
higher risk | 4 |
containment measures | 4 |
positive cultures | 4 |
identify viruses | 4 |
previous report | 4 |
risk assessment | 4 |
brew assays | 4 |
gfp fusion | 4 |
still unclear | 4 |
novel pathogen | 4 |
undescribed coronavirus | 4 |
qpcr mix | 4 |
chronic lung | 4 |
review editing | 4 |
multiple stages | 4 |
multiple logistic | 4 |
valent pneumococcal | 4 |
discrepant analysis | 4 |
convalescent plasma | 4 |
additionally positive | 4 |
antigen testing | 4 |
flow tests | 4 |
kiv conventional | 4 |
acid extract | 4 |
five patients | 4 |
worldwide shortage | 4 |
limited data | 4 |
result availability | 4 |
increased sensitivity | 4 |
study provides | 4 |
seasonal incidence | 4 |
incidence rate | 4 |
study included | 4 |
also assessed | 4 |
phylogenetic tree | 4 |
first week | 4 |
value difference | 4 |
pcr protocol | 4 |
enzyme immunoassay | 4 |
eight consecutive | 4 |
nuclisens easymag | 4 |
rna sample | 4 |
automated system | 4 |
china clinical | 4 |
threshold line | 4 |
using sas | 4 |
viral exclusive | 4 |
participating laboratories | 4 |
disease prevention | 4 |
rna control | 4 |
prospective studies | 4 |
published reports | 4 |
laboratories will | 4 |
specific viral | 4 |
realamp kit | 4 |
negative respiratory | 4 |
formal analysis | 4 |
mixed infections | 4 |
rvp fast | 4 |
laboratory staff | 4 |
study describes | 4 |
dad sofia | 4 |
seasonal coronavirus | 4 |
bronchoalveolar lavages | 4 |
empirical antibiotics | 4 |
negative pcr | 4 |
viral agent | 4 |
readily available | 4 |
hubei province | 4 |
institut pasteur | 4 |
pneumococcal conjugate | 4 |
kong outbreak | 4 |
cell carcinoma | 4 |
two cases | 4 |
many manufacturers | 4 |
strains isolated | 4 |
patient group | 4 |
samples including | 4 |
biosafety level | 4 |
mortality associated | 4 |
negative percent | 4 |
automation system | 4 |
first time | 4 |
positive panel | 4 |
viral coinfection | 4 |
genetic characterization | 4 |
genetic clustering | 4 |
individuals diagnosed | 4 |
combining igm | 4 |
copy numbers | 4 |
transcription mediated | 4 |
illness associated | 4 |
extensively exposed | 4 |
collection time | 4 |
conducted using | 4 |
igg elisa | 4 |
results show | 4 |
acute viral | 4 |
cost analysis | 4 |
without viral | 4 |
two automated | 4 |
increase throughput | 4 |
equivalent sensitivity | 4 |
georges pompidou | 4 |
qualitative detection | 4 |
seven different | 4 |
selected based | 4 |
common colds | 4 |
acid extracts | 4 |
assay specificity | 4 |
cell line | 4 |
demand testing | 4 |
invalid results | 4 |
higher cd | 4 |
laboratory technicians | 4 |
standard deviations | 4 |
three sample | 4 |
resolver test | 4 |
collected samples | 4 |
patient pt | 4 |
etiologic agents | 4 |
prospective hospital | 4 |
one ev | 4 |
hrv isolates | 4 |
ev infection | 4 |
vzv pcr | 4 |
new rhinovirus | 4 |
probe concentrations | 4 |
repeated nucleic | 4 |
recovery rate | 4 |
varicella zoster | 4 |
total antibodies | 4 |
confirmed covid | 4 |
based study | 4 |
substantial number | 4 |
time points | 4 |
human pegivirus | 4 |
mers cov | 4 |
ki polyomaviruses | 4 |
patients developed | 4 |
previous runs | 4 |
high rates | 4 |
specimens positive | 4 |
tested individually | 4 |
triplex assay | 4 |
serum sample | 4 |
cells infected | 4 |
virus development | 4 |
three categories | 4 |
information regarding | 4 |
pilot study | 4 |
early treatment | 4 |
blocking solution | 4 |